Top Seller
047C8BACD51E9D216D9EC9292AB94088
047C8BACD51E9D216D9EC9292AB94088
A8E20489CDE37236802BBD76C023858C

OraVerse™ Injection Box of 10

In Stock in PA, FL, IN, TX, NV

Septodont # 99210

Benco Product # 4165-575

Product Line: 1210H - ANESTHETIC - EFFECT REVERSAL

Pricing shown is suggested retail. To view your price, please log in.

Current Promotions

  • Septodont Oraverse: Buy 1 Ten-Pack, Get 1 Ten-Pack Free Automatically with Your Order! - valid 1/1/2019 to 12/31/2019

Product Details

OraVerse™ Phentolamine Mesylate OraVerse is the first and only local anesthesia reversal agent. In clinical trials, the median time to recovery of normal sensation in the upper lip was 50 minutes for OraVerse patients vs. 133 minutes for the control group and in the lower lip was 70 minutes for OraVerse patients vs. 155 minutes for the control. In clinical trials. OraVerse patients were more quickly able to smile, speak, drink normally and minimize drooling. Market research shows 88% of patients may be interested in receiving a product like OraVerse. Includes: (1) Blister of (10) 1.7ml glass cartridges. Total of (10) cartridges. In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents.

Loading Accessory Information...

Customer Questions & Answers

Loading Customer Q & A...